ES2290046T3 - Procedimiento para caracterizar un estado biologico, mediante el empleo de perfiles calibrados de expresion genica. - Google Patents
Procedimiento para caracterizar un estado biologico, mediante el empleo de perfiles calibrados de expresion genica. Download PDFInfo
- Publication number
- ES2290046T3 ES2290046T3 ES00944977T ES00944977T ES2290046T3 ES 2290046 T3 ES2290046 T3 ES 2290046T3 ES 00944977 T ES00944977 T ES 00944977T ES 00944977 T ES00944977 T ES 00944977T ES 2290046 T3 ES2290046 T3 ES 2290046T3
- Authority
- ES
- Spain
- Prior art keywords
- profile data
- calibrated
- panel
- sample
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 82
- 230000014509 gene expression Effects 0.000 title description 86
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 117
- 239000000470 constituent Substances 0.000 claims abstract description 87
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 64
- 238000005259 measurement Methods 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims description 78
- 239000008280 blood Substances 0.000 claims description 62
- 210000004369 blood Anatomy 0.000 claims description 61
- 229940079593 drug Drugs 0.000 claims description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 206010061218 Inflammation Diseases 0.000 claims description 19
- 230000004054 inflammatory process Effects 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 16
- 231100000419 toxicity Toxicity 0.000 claims description 14
- 230000001988 toxicity Effects 0.000 claims description 14
- 108020004999 messenger RNA Proteins 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 238000011156 evaluation Methods 0.000 claims description 9
- -1 TGF-b Proteins 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 7
- 230000010224 hepatic metabolism Effects 0.000 claims description 7
- 238000011002 quantification Methods 0.000 claims description 7
- 206010067484 Adverse reaction Diseases 0.000 claims description 5
- 101150071146 COX2 gene Proteins 0.000 claims description 5
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 claims description 5
- 101150085950 IL10 gene Proteins 0.000 claims description 5
- 101150083678 IL2 gene Proteins 0.000 claims description 5
- 101150000187 PTGS2 gene Proteins 0.000 claims description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 5
- 230000006838 adverse reaction Effects 0.000 claims description 5
- 238000003753 real-time PCR Methods 0.000 claims description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 claims description 3
- 101150081923 IL4 gene Proteins 0.000 claims description 3
- 102100037850 Interferon gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 claims description 3
- 101150062589 PTGS1 gene Proteins 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000012239 Developmental disease Diseases 0.000 claims description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 101150015560 IL5 gene Proteins 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 36
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 140
- 239000000523 sample Substances 0.000 description 89
- 239000003795 chemical substances by application Substances 0.000 description 85
- 239000002158 endotoxin Substances 0.000 description 62
- 229920006008 lipopolysaccharide Polymers 0.000 description 61
- 150000001875 compounds Chemical class 0.000 description 48
- 230000000694 effects Effects 0.000 description 47
- 238000011282 treatment Methods 0.000 description 36
- 229940124597 therapeutic agent Drugs 0.000 description 32
- 230000000875 corresponding effect Effects 0.000 description 30
- 239000000203 mixture Substances 0.000 description 25
- 235000014134 echinacea Nutrition 0.000 description 22
- 238000001727 in vivo Methods 0.000 description 21
- 238000000338 in vitro Methods 0.000 description 20
- 244000133098 Echinacea angustifolia Species 0.000 description 19
- 230000004044 response Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 241000282414 Homo sapiens Species 0.000 description 14
- 239000002417 nutraceutical Substances 0.000 description 14
- 235000021436 nutraceutical agent Nutrition 0.000 description 14
- 230000003110 anti-inflammatory effect Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- 229960004584 methylprednisolone Drugs 0.000 description 12
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 239000002260 anti-inflammatory agent Substances 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 229940121363 anti-inflammatory agent Drugs 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 229960000485 methotrexate Drugs 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 241000208983 Arnica Species 0.000 description 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 108010047620 Phytohemagglutinins Proteins 0.000 description 8
- 241000295644 Staphylococcaceae Species 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000001885 phytohemagglutinin Effects 0.000 description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 235000008216 herbs Nutrition 0.000 description 6
- 229940013798 meclofenamate Drugs 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 5
- 108010002616 Interleukin-5 Proteins 0.000 description 5
- 102100023132 Transcription factor Jun Human genes 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 239000012678 infectious agent Substances 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 4
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000000743 Interleukin-5 Human genes 0.000 description 4
- 102100027584 Protein c-Fos Human genes 0.000 description 4
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000003466 anti-cipated effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 241000258180 Echinacea <Echinodermata> Species 0.000 description 3
- 101150101999 IL6 gene Proteins 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000012606 in vitro cell culture Methods 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 241001632410 Eleutherococcus senticosus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010073306 Exposure to radiation Diseases 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 2
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 2
- 101000617823 Homo sapiens Solute carrier organic anion transporter family member 6A1 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 101100508567 Mus musculus Il7 gene Proteins 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 2
- 102100021991 Solute carrier organic anion transporter family member 6A1 Human genes 0.000 description 2
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 2
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000010228 ex vivo assay Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 230000013707 sensory perception of sound Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 231100000440 toxicity profile Toxicity 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101150025117 IL3 gene Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 208000036647 Medication errors Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010036909 Prostate cancer metastatic Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 101150040974 Set gene Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000003131 biological toxin Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 238000012826 global research Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940072651 tylenol Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14154299P | 1999-06-28 | 1999-06-28 | |
| US141542P | 1999-06-28 | ||
| US19552200P | 2000-04-07 | 2000-04-07 | |
| US195522P | 2000-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2290046T3 true ES2290046T3 (es) | 2008-02-16 |
Family
ID=26839213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00944977T Expired - Lifetime ES2290046T3 (es) | 1999-06-28 | 2000-06-28 | Procedimiento para caracterizar un estado biologico, mediante el empleo de perfiles calibrados de expresion genica. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1198585B1 (enExample) |
| JP (1) | JP2004528526A (enExample) |
| KR (1) | KR20020079364A (enExample) |
| AT (1) | ATE364721T1 (enExample) |
| AU (1) | AU784233B2 (enExample) |
| CA (1) | CA2378008A1 (enExample) |
| CY (1) | CY1107733T1 (enExample) |
| DE (1) | DE60035196T2 (enExample) |
| DK (1) | DK1198585T3 (enExample) |
| ES (1) | ES2290046T3 (enExample) |
| IL (2) | IL147349A0 (enExample) |
| PT (1) | PT1198585E (enExample) |
| WO (1) | WO2001025473A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7473528B2 (en) | 1999-01-06 | 2009-01-06 | Genenews Inc. | Method for the detection of Chagas disease related gene transcripts in blood |
| US6960439B2 (en) | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| US7590493B2 (en) | 2000-07-31 | 2009-09-15 | Ocimum Biosolutions, Inc. | Methods for determining hepatotoxins |
| AUPR480901A0 (en) * | 2001-05-04 | 2001-05-31 | Genomics Research Partners Pty Ltd | Diagnostic method for assessing a condition of a performance animal |
| US7415358B2 (en) | 2001-05-22 | 2008-08-19 | Ocimum Biosolutions, Inc. | Molecular toxicology modeling |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US7026121B1 (en) | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US20030096264A1 (en) * | 2001-06-18 | 2003-05-22 | Psychiatric Genomics, Inc. | Multi-parameter high throughput screening assays (MPHTS) |
| US7447594B2 (en) | 2001-07-10 | 2008-11-04 | Ocimum Biosolutions, Inc. | Molecular cardiotoxicology modeling |
| AU2002365904A1 (en) * | 2001-07-10 | 2003-09-04 | Gene Logic, Inc. | Cardiotoxin molecular toxicology modeling |
| CA2457799C (en) | 2001-08-21 | 2014-05-27 | Ventana Medical Systems, Inc. | Method and quantification assay for determining c-kit/scf/pakt status |
| US6964850B2 (en) | 2001-11-09 | 2005-11-15 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| US7469185B2 (en) | 2002-02-04 | 2008-12-23 | Ocimum Biosolutions, Inc. | Primary rat hepatocyte toxicity modeling |
| AU2003272438B2 (en) | 2002-09-20 | 2009-04-02 | New England Biolabs, Inc. | Helicase dependent amplification of nucleic acids |
| US7662594B2 (en) | 2002-09-20 | 2010-02-16 | New England Biolabs, Inc. | Helicase-dependent amplification of RNA |
| AU2002952696A0 (en) * | 2002-11-14 | 2002-11-28 | Genomics Research Partners Pty Ltd | Status determination |
| US7778782B1 (en) | 2002-12-17 | 2010-08-17 | Entelos, Inc. | Peroxisome proliferation activated receptor alpha (PPARα) signatures |
| US7396645B1 (en) | 2002-12-17 | 2008-07-08 | Entelos, Inc. | Cholestasis signature |
| AU2003303238B2 (en) * | 2002-12-19 | 2010-07-22 | Life Technologies Corporation | Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles |
| US7422854B1 (en) | 2002-12-20 | 2008-09-09 | Entelos, Inc. | Cholesterol reduction signature |
| US7519519B1 (en) | 2002-12-20 | 2009-04-14 | Entelos, Inc. | Signature projection score |
| AU2003901196A0 (en) * | 2003-03-17 | 2003-04-03 | Commonwealth Scientific And Industrial Research Organisation | Analysis method |
| EP2128270B1 (en) | 2003-08-08 | 2012-10-03 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
| JPWO2005087924A1 (ja) * | 2004-02-18 | 2008-01-31 | 株式会社三重ティーエルオー | Ｄｎａチップ並びに疾患関連遺伝子の抽出方法 |
| WO2006138561A2 (en) | 2005-06-16 | 2006-12-28 | Source Mdx | Gene expression profiling for identification and monitoring of multiple sclerosis |
| AU2006294477A1 (en) | 2005-09-27 | 2007-04-05 | Source Mdx | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
| CA2652239A1 (en) * | 2006-05-16 | 2007-11-29 | Source Mdx | Assessment of effect of an agent on a human biological condition using rodent gene expression panels |
| US20100196889A1 (en) | 2006-11-13 | 2010-08-05 | Bankaitis-Davis Danute M | Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer |
| US20120009581A1 (en) | 2008-07-08 | 2012-01-12 | Bankaitis-Davis Danute M | Gene Expression Profiling for Predicting the Survivability of Prostate Cancer Subjects |
| CA2748823A1 (en) | 2009-01-06 | 2010-07-15 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for the identification, monitoring, and treatment of prostate cancer |
| US9074248B1 (en) | 2012-12-18 | 2015-07-07 | Qiagen Gmbh | Primers for helicase dependent amplification and their methods of use |
| CN103525926B (zh) * | 2013-10-08 | 2016-03-23 | 浙江大学 | 一种基于基因表达谱的药物毒性个体易感性基因标志物的筛选方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643765A (en) * | 1993-04-06 | 1997-07-01 | University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| US5922184A (en) * | 1997-07-21 | 1999-07-13 | Bio-Rad Laboratories, Inc. | Computer-directed detection of paraproteins |
| EP0960214A4 (en) * | 1996-12-06 | 2004-08-04 | Urocor Inc | Diagnosis of disease status on HAnd from mRNA profiles |
| US5968784A (en) * | 1997-01-15 | 1999-10-19 | Chugai Pharmaceutical Co., Ltd. | Method for analyzing quantitative expression of genes |
| GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| AU9217198A (en) * | 1997-09-03 | 1999-03-22 | Oncormed | Method for predicting prognosis and treatment response for genetically based abnormalities |
| AU743011B2 (en) * | 1997-09-12 | 2002-01-17 | Phri Properties, Inc. | Non-competitive co-amplification methods |
| DE69829402T2 (de) * | 1997-10-31 | 2006-04-13 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Expressionsprofile in adulten und fötalen organen |
-
2000
- 2000-06-28 DK DK00944977T patent/DK1198585T3/da active
- 2000-06-28 AU AU58985/00A patent/AU784233B2/en not_active Expired
- 2000-06-28 JP JP2001528624A patent/JP2004528526A/ja active Pending
- 2000-06-28 EP EP00944977A patent/EP1198585B1/en not_active Revoked
- 2000-06-28 WO PCT/US2000/017846 patent/WO2001025473A1/en not_active Ceased
- 2000-06-28 AT AT00944977T patent/ATE364721T1/de active
- 2000-06-28 KR KR1020017016828A patent/KR20020079364A/ko not_active Ceased
- 2000-06-28 DE DE60035196T patent/DE60035196T2/de not_active Revoked
- 2000-06-28 ES ES00944977T patent/ES2290046T3/es not_active Expired - Lifetime
- 2000-06-28 CA CA002378008A patent/CA2378008A1/en not_active Abandoned
- 2000-06-28 PT PT00944977T patent/PT1198585E/pt unknown
- 2000-06-28 IL IL14734900A patent/IL147349A0/xx unknown
-
2001
- 2001-12-26 IL IL147349A patent/IL147349A/en active IP Right Grant
-
2007
- 2007-09-12 CY CY20071101178T patent/CY1107733T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1198585A1 (en) | 2002-04-24 |
| IL147349A0 (en) | 2002-08-14 |
| DE60035196T2 (de) | 2008-02-21 |
| EP1198585B1 (en) | 2007-06-13 |
| DE60035196D1 (de) | 2007-07-26 |
| AU5898500A (en) | 2001-05-10 |
| DK1198585T3 (da) | 2007-10-15 |
| PT1198585E (pt) | 2007-09-20 |
| AU784233B2 (en) | 2006-02-23 |
| WO2001025473A1 (en) | 2001-04-12 |
| KR20020079364A (ko) | 2002-10-19 |
| IL147349A (en) | 2011-12-29 |
| JP2004528526A (ja) | 2004-09-16 |
| WO2001025473A9 (en) | 2002-08-08 |
| ATE364721T1 (de) | 2007-07-15 |
| CY1107733T1 (el) | 2013-04-18 |
| CA2378008A1 (en) | 2001-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2290046T3 (es) | Procedimiento para caracterizar un estado biologico, mediante el empleo de perfiles calibrados de expresion genica. | |
| Pathmanaban et al. | Association of genetic predisposition with solitary schwannoma or meningioma in children and young adults | |
| Wienke | Frailty models in survival analysis | |
| Schmalbach et al. | Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma | |
| JP5236856B2 (ja) | 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定 | |
| Slonim et al. | Getting started in gene expression microarray analysis | |
| Shi et al. | Co-expression module analysis reveals biological processes, genomic gain, and regulatory mechanisms associated with breast cancer progression | |
| US20120277998A1 (en) | System And Methods For Characterizing A Biological Condition Or Agent Using Selected Gene Expression Profiles | |
| EP2066809A2 (en) | Gene expression profiling for identification, monitoring and treatment of transplant rejection | |
| JP2005508505A5 (enExample) | ||
| Miele et al. | DNA methylation profiling for diagnosing undifferentiated sarcoma with capicua transcriptional receptor (CIC) alterations | |
| JP7141029B2 (ja) | データベースを構築する方法 | |
| CN1751129B (zh) | 利用基因表达图谱鉴定、监测和治疗传染病和表征传染病相关炎症 | |
| EP2313531A1 (en) | Gene expression profiling for identification, monitoring, and treatment of osteoarthritis | |
| AU2003303238A2 (en) | Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles | |
| Sutherland et al. | Canadian lung tissue biobank with associated clinical data supporting respiratory research for four decades | |
| Grossman et al. | Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons | |
| Xu et al. | Pathway cross-talk analysis in detecting significant pathways in Barrett’s esophagus patients | |
| HK1169190A (en) | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles | |
| Dolci et al. | P255 Avascular osteonecrosis of the jawbones in oncological patients related to the use of bisphophonates: the role of a correct diagnosis as the first step of the treatement planning | |
| Abujudeh | Cancer Research UK Cambridge Institute University of Cambridge, United Kingdom | |
| Staff | IMA offers powerful tools to aid translational researchers | |
| Thorburn | Mitochondrial disorders in australasian children: from enzymes and metabolites to genes | |
| Shi et al. | Research article Co-expression module analysis reveals biological processes, genomic gain, and regulatory mechanisms associated with breast cancer progression | |
| Giles | Microarray-based expression profiling: improving data mining and the link to biological knowledge pools. |